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Background: Current therapeutic standard for locally advanced rectal cancer is the neoadjuvant radiochemotherapy
with total mesorectal excision. Diarrhoea is the main acute side effect, induced by the dose to the small-bowel,
frequently leading to a treatment modification. Aim of this study was to analyse the differences between the irradiated
small-bowel volumes and the occurrence of acute diarrhea during combined radiochemotherapy for rectal cancer.
Methods: 45 patients treated with a neoadjuvant radiochemotherapy (three-field box 50.4 Gy; Cetuximab,
Capecitabine, Irinotecan) for locally advanced rectal cancer within a prospective phase I/II study were evaluated. Based
on the dose-volume histograms, the small-bowel volumes receiving doses of 5, 10 … 45 Gy (V5, V10 …V45) were
calculated and compared with the prospectively documented small- bowel toxicities.
Results: There was a statistically significant difference between irradiated small-bowel volumes and the severity of
therapy related diarrhoea. The strongest validity concerning the risk of developing a grade 2–3 diarrhoea was seen at a
dose level of 5 Gy (V 5) with a small-bowel volume of 291.94 cc. Patients with V 5 > 291.94 cc had significantly more
often grade 2–3 diarrhoea, than patients with V5 below this cut-off value (82% vs. 29%; p < 0.0001).
Conclusions: In the inverse treatment planning of rectal caner patients the small-bowel volume receiving 5 Gy should
be limited to about 300 cc.
Keywords: Locally advanced rectal cancer, Radiation enteritis, Dose-volume histogram, Dose-volume constraints,
Neoadjuvant radiochemotherapyIntroduction
Since the CAO/AIO/ARO-94 trial [1,2] neoadjuvant ra-
diochemotherapy (nRCT) followed by a total mesorectal
excision (TME) is the standard treatment for locally ad-
vanced rectal cancer (LARC).
Five -fluoruracil (5-FU) or Capecitabine based chemo-
therapies concurrent to external beam radiotherapy (EBRT)
are the most frequently used regimes. The last years
new drugs such as Irinotecan, Oxaliplatin or Cetuximab* Correspondence: tina.reis@umm.de
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unless otherwise stated.combined with 5-FU/Capecitabine were introduced to
improve treatment results.
Acute diarrhoea is one of the most common acute se-
quela of pelvic radiochemotherapy in up to 12-39% [3,4].
It often requires treatment and sometimes causes a ther-
apy interruption resulting in a reduced efficacy. Although
acute gastrointestinal toxicity is multifactorial [5], some
studies described a statistical significant relationship be-
tween irradiated small-bowel volume and treatment in-
duced diarrhoea during radiochemotherapy for rectal
cancer [6,7]. Therefore an optimization of radiotherapy
planning to spare small-bowel should be aspired. Datais is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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(DVH) are to be optimized are rare [8,9].
Aim of this study was to analyse the differences between
the irradiated small-bowel volume and the occurrence/se-
verity of acute diarrhoea during combined radiochemo-
therapy with Capecitabine, Irinotecan and Cetuximab,
using information extracted from the 3D treatment plan-
ning and the individual DVH from patients treated for
LARC within a prospective study [10,11]. Moreover we
identified cut-off values for the irradiated small-bowel vol-
umes associated with diarrhoea grade 2–3. Additionally
the difference between a high dose to a small-bowel vol-
ume and a little dose to a large small-bowel volume (“a lot
to a little” or a “little to a lot”) will be discussed.
Methods and materials
Patients
45 patients treated with a nRCT (Cetuximab, Capecita-
bine, Irinotecan) for LARC between 2004 and 2007 were
evaluated. All patients were treated in a prospective
phase I/II study [10,11]. Median age was 60 years (range,
41–80 years).
























Abdominoperineal resection 9All studies on humans described in the present manu-
script were carried out with the approval of the respon-
sible ethics committee and in accordance with national
law and the Helsinki Declaration of 1975 (in its current
revised form), Informed consent was obtained from all
patients included in studies.
Treatment
All patients received weekly Cetuximab (400 mg/m2 day
1 and 250 mg/m2 days 8, 15, 22, and 29) 2 h before
radiotherapy, weekly Irinotecan (40 mg/m2 days 1, 8, 15,
22, and 29) 1 h before radiotherapy, and Capecitabine
orally twice daily (500 mg/m2 days 1–38).
Simulation and irradiation was done in prone position
using a belly board. All patients received a 3D CT-based
treatment plan. The abdomen and pelvis were scanned
with 0.5-1.0 cm thick continuous slices.
The clinical target volume (CTV) included the primary
tumour and the regional lymph nodes (mesorectal, pre-
sacral, internal/common iliac). The upper border of the
CTV was at the L5–S1 interspace for cN0 and at L4–L5
for cN+ patients. The planning target volume (PTV) was
defined as the CTV with 1 cm margins. The lower
border of the PTV depends on the level of the primary
tumour (rectal cancer > 6 cm from anocutaneous line:
above the anal sphincter complex, provided a 3 cm mar-
gin from distal tumour edge; rectal cancer ≤ 6 cm from
anocutaneous line: perineum). Organs at risk like the
bladder or small bowel were contoured not exceeding
L4. The small bowel was contoured as individual small
bowel loops.
Radiotherapy was delivered with a linear accelerator
using 18–23 MeV photons and a three-field box tech-
nique consisting of a posterior-anterior and 2 lateral
fields. A total dose of 50.4 Gy was given in daily frac-
tions of 1.8 Gy, 5 days a week. After a dose of 45 Gy, an
additional dose of 5.4 Gy was given to the boost volume
using a shrinking field technique based on treatment
planning CT scan after oral contrast administration. The
boost volume was defined as primary tumour including
corresponding mesorectum with 2 cm margins circum-
ferential and if possible 5 cm margins cranial.
Toxicity scoring
Data were obtained retrospectively using the irradiation
protocols and patient documents of the Department of
Radiation Oncology and of the III. Medical Clinic,
University Medical Centre Mannheim. Diarrhoea as a
measure of acute small-bowel toxicity during nRCT was
chosen as primary endpoint. Toxicity scoring was done
prospectively during the whole radiochemotherapy ses-
sion by use of questionnaires. The degree of diarrhoea
was classified according to the NCI Common Toxicity
Criteria (CTC) scale, version 3.0 (Table 2). In the
Table 2 NCI Common toxicity criteria (CTC) scale, version 3.0 of diarrhoea
Diarrhoea grade 1 Grade 2 Grade 3 Grade 4 Grade 5
Increase of <4 stools per day
over baseline; mild increase
in ostomy output
Increase of 4 – 6 stools per day over
baseline; IV fluids indicated <24 hours;
moderate increase in ostomy output
compared to baseline; not
interfering with ADL*
Increase of ≥7 stools per day
over baseline; incontinence; IV
fluids ≥24 hours; hospitalization;
severe increase in ostomy output






*Activities of Daily Living.
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able (grade 0–1 vs. 2–3). This classification was chosen
because a diarrhoea grade ≥ 2 means an increase of 4 – 6
stools per day over baseline, which is a clinically important
side effect, often leading to a therapy modification.
Treatment plan analysis
For treatment planning small-bowel (from the Douglas
pouch up to the L5-S1 region), large-bowel and other or-
gans at risk were contoured based on the CT simulation
scan with oral contrast.
From the extracted DVH of the PTV the small-bowel
volumes that received doses of 5, 10, 15, 20, 25, 30, 35,
40 and 45 Gy (V5, V 10, …V45) were calculated. The de-
termined small-bowel volumes were compared with the
grade of the small-bowel toxicity. The volumes were
only calculated in absolute numbers (cc) because the en-
tire small-bowel was not contoured in all patients and
therefore relative numbers would not be representative.
Statistics
All analyses were performed using the IBM Statistical
Package for Social Sciences software, version 19 (SPSS
Inc., Chicago, IL). Data are presented as frequencies, me-
dians, minimum and maximum values, averages and stand-
ard deviations. Spearman’s rank correlation coefficient was
used. Pearson’s chi-squared test or rather Fisher’s exact test
was used to assess changes in frequencies. Mann–Whitney
U-Test or rather Student’s t-test was used to assess changes
in averages.
Receiver operating characteristic (ROC) analyses were
used to identify cut-off values for the irradiated small-bowel
volumes associated with grade 2–3 diarrhoea. The area
under the curve (AUC) and 95% confidence intervals (CIs)
were determined for each ROC analysis. Cut-off values
were identified using the Youden index, which is calculated
as a linear combination of sensitivity and specificity (Y =
sensitivity + specificity-1). The maximum of the Youden
index indicates an optimal cut-off point [12]. A two-sided p
value of < 0.05 was considered statistically significant.
Results
Clinical outcome
43 of the 45 patients received the planned total dose of
50.4 Gy. Two patients stopped radiotherapy early, onepatient after a dose of 34.20 Gy because of a cholangitis,
and one patient after a dose of 43.2 Gy of unknown
reason.
The average volume of the small-bowel was 585 cc
(range, 121–983 cc; Figure 1). The average volume of
the rectum was 1671 cc (range, 1061–2254 cc).
The median/average dose intensities (applied dose di-
vided by the planned dose multiplied by 100 [%]) of
Capecitabine, Irinotecan and Cetuximab were: Capecita-
bine 100/89 (range, 29–100); Irinotecan 100/93 (range,
33–100); Cetuximab 100/92 (range, 29–100).
20 patients received chemotherapy to 100%. In the
remaining cases chemotherapy was interrupted and con-
tinued with reduced dose intensity due to different
intolerances.
Toxicity
Diarrhoea was the most frequent acute side effect. Overall
39 patients suffered from diarrhoea as follows: 6, 11, 15
and 13 patients had grade 0, 1, 2 and 3 respectively. Other
acute side effects were: nausea (19 patients with grade 1 or
2, one patient with grade 3); abdominal pain (15 patients
with grade 1 or 2, two patients with grade 3).
Comparison of toxicity & determination of cut-off doses
17 patients with grade 0–1 versus 28 patients with grade
2–3 diarrhoea were compared. The average V5, V10,
V15 and V30 was significantly larger in patients experi-
encing grade 2–3 diarrhoea compared to patients with
grade 0–1 diarrhoea (p = 0.002, p = 0.007, p = 0.005 and
p = 0.049; Figure 2).
ROC analyses were used to identify cut-off values pre-
dicting a diarrhoea grade 2–3. For the irradiated small-
bowel volumes, which received a dose of 5 to 30 Gy, we
had seen areas under the curve (AUC’s) between 0.68
und 0.77 (p < 0.05, Table 3). The highest AUC values
were achieved for the V5 and the V15. The best cut-off
point predicting a Grade 2–3 diarrhoea was seen for the
V5 with a threshold-volume of the irradiated small-bowel
of 291.94 cc (sensitivity 82%, specificity 71%, Youden-
Index 0.53; Table 4). 23 of 28 patients (82%) with V 5 >
291.94 cc developed a grade 2–3 diarrhoea versus only 5
of 17 patients (29%) with V5 ≤ 291. 94 cc (p = 0.001).
Moreover an irradiated small-bowel volume of
125.55 cc for a dose of 15 Gy could be determined as a
Figure 1 Averages of the irradiated small bowel volume receiving 5 – 45 Gy (V5-V45 Gy).
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64% and 82% this ratio is less significant and due to the low
sensitivity for the clinical routine only restrictively applicable.Discussion
A significant difference between the irradiated small-bowel
volumes and the severity of radiation induced diarrhoea
were found, where the average volume of irradiated small-
bowel was significantly larger in patients with grade 2–3
versus the volume in patients with grade 0–1 diarrhoea.
Similar results were shown in recent studies. Gunnlaugsson
et al. [6] found, that patients with diarrhoea grade 2+ had an
average larger absolute volume of irradiated small-bowel for
all cut-off doses. Baglan et al. [13] also described a staticallyFigure 2 Dose-volume histograms for small bowel. Dose-volume histog
small-bowel volume in individual patients receiving 5, 10…45 Gy. Lines indlarger volume of irradiated small-bowel at each 5 Gy level
between 5–40 Gy in patients developing grade 3+ toxicity.
In the study of Gunnlaugsson et al. [6] 52% of the pa-
tients with an irradiated small-bowel volume of > 150 cc
with >15 Gy showed a clinically significant diarrhoea in
comparison to only 11% of the patients with >15 Gy
in ≤150 cc of small-bowel. Similar results have been re-
ported by Baglan et al. [13]. No patient with an irradiated
small-bowel volume < 150 cc at a dose level of >15 Gy de-
veloped a grade 3+ diarrhoea versus 50% of the patients
with a small-bowel volume of ≥150 cc.
In our study a classification in grade 0–1 versus grade 2–
3 diarrhoea was chosen, because already grade 2+ diarrhoea
may lead to a therapy modification and is therefore clinic-
ally relevant. We observed statistically significant higherrams classified in diarrhoea grade 0–1 versus grade 2–3. Dots indicate
icate average volumes as a function of dose level.
Table 3 ROC-analyses for determination of optimal
thresholds for diarrhoea grade 2-3
95% confidence interval
AUC p Lower confidence limit Upper confidence limit
V5 0.768 0.003 0.616 0.920
V10 0.716 0.016 0.557 0.875
V15 0.752 0.005 0.597 0.907
V20 0.723 0.013 0.558 0.887
V25 0.708 0.020 0.541 0.875
V30 0.676 0.049 0.508 0.845
V35 0.671 0.056 0.502 0.841
V40 0.651 0.092 0.481 0.822
V45 0.500 1.000 0.318 0.682
*Area Under the Curve.
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bowel volume >291.94 cc in comparison to the patients
with an irradiated small-bowel volume ≤291.94 at a dose
level of 5 Gy. 82% of the patients with a small-bowel vol-
ume of >291.94 with 5 Gy had grade 2–3 diarrhoea, but
only 29% of the patients with a small-bowel volume below
this cut-off value. Therefore we suggest that the irradiated
small-bowel volume receiving 5 Gy should be kept lower
than 300 cc during treatment planning. However it must be
stressed, that this analysis could be biased by the fact that
small bowel, in the preoperative setting, may move during
the treatment and thus a specific dose to a little part of the
small bowel could be different at the end of the treatment
than the dose calculated on the CT scan of treatment plan.
Overall therapy induced diarrhoea in our evaluation is
unusually high. Overall 80% of the patients developed a
diarrhoea during therapy, 28.9% of these patients a grade
3 diarrhoea. This could be caused by the additional appli-
cation of systemic therapy, especially irinotecan and cetux-
imab. Neoadjuvant radiotherapy alone in patients with
locally advanced rectal cancer has significantly lower over-
all toxicities compared to neoadjuavnt combined 5-FUTable 4 Determination of optimal cut-off values for the
irradiated small-bowel volume by varying radiation dose
Cut-off values (cc*) Sensitivity (%) Specificity (%) Youden
V5 291.94 82.1 70.6 .53
V10 321.52 64.3 76.5 .41
V15 125,26 64.3 82.4 .47
V20 96,.84 53.6 88.2 .42
V25 13.50 100.0 41.2 .41
V30 9.62 96.4 41.2 .38
V35 7.03 96.4 41.2 .38
V40 4.85 89.3 41.2 .31
V45 1.24 67.9 47.1 .15
*cubic centimeter.based radiochemotherapy (2.9% vs. 14.9%, p < 0.001) [14].
Nevertheless, due to significant higher local control rates
neoadjuvant radiochemotherapy followed by a total mesor-
ectal excision (TME) is the standard treatment for locally
advanced rectal cancer [15]. 5-FU must be administered as
a continuous infusion during radiation, therefore the devel-
opment of tolerable and efficient agents that do not require
continuous infusion like oral fluoropyrimidine, e.g. capec-
tiabine were promoted. The definitive demonstration that
efficacy of concurrent radiochemotherapy with capecita-
bine is similar to 5-FU based radiochemotherapy has been
provided by Hofheinz [16] and O’Connell et al. [17]. Re-
ported grade 3+ diarrhea rates under capecitabine based
radiochemotherapy were between 4%-24% [18-20]. In the
phase III study of Hofheinz et al. overall 53% of the pa-
tients after capecitabine based radiochemotherapy suffer
from diarrhea, whereas only 9% of the patients developed a
grade 3+ diarrhea [16]. One approach to improve out-
comes in rectal cancer is to deliver a second radiation
sensitizing drug with effective systemic activity. Irinote-
can is therefore good candidate. Compared to capecitabine
alone combined radiochemotherapy with capectabine and
irinotecan has higher overall diarrhea rates with similar
grade 3+ diarrhea rates. In the study of Ugidos et al. [21]
64% of the patients after Irinotecan and capecitabine ra-
diochemotherapy developed a therapy induced diarrhoea,
28% a grade 3+ diarrhea. In another phase II study an
overall diarrhoe rate of 89% with a grade 3+ diarrhoea rate
of 11% was reported [22]. The ongoing ARISTOTLE trial
will provide a definitive answer about the benefit of adding
irinotecan to capecitabine in the neoadjuvant setting [23].
Moreover a few studies showed an increased rate of
side effects, especially accumulated toxicities of the
small-bowel, during radiochemotherapy combined with
Cetuximab [24,25], too. Nevertheless, although the abso-
lute height of the observed side effects may be different
after less toxic chemotherapy, the presented results can
be extrapolated regarding thresholds and recommenda-
tions to standard chemotherapy. Furthermore, for rectal
cancer acute effects on large bowel are difficult to distin-
guish from effects on small bowel.
For a long time it was controversially discussed if the
dose distribution“ a lot to a little” or “a little to a lot”,
which means a high dose to a small volume or a little dose
to a large normal tissue volume is more critical for the in-
duction of toxicity. This is especially relevant for intensity-
modulated radiotherapy (IMRT), because IMRT typically
delivers a low dose to a greater normal tissue volume than
3D conformal radiotherapy. So far this analysis was mainly
done for the irradiation of lung cancer. Willner et al. [26]
performed a systematic analysis of pneumonitis risk from
DVH-parameters of the lung in patients with lung cancer
treated with 3D conformal radiotherapy. Their data
showed, that it is reasonable to disperse a low radiation
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volume (>40 Gy) could be reduced.
In the treatment of pelvic tumours there are no clinically
relevant data available up to now, discussing this item. Our
data indicate in contrast to the situation for the lung a
higher risk for diarrhoea, if large small-bowel volumes re-
ceive a low dose than other way round. Therefore we con-
clude” a lot to a little” is more favourable than “a little to a
lot”. An illustrative presentation gives Figure 2 where the
greatest differences between the two collectives with grade
0–1 and grade 2–3 diarrhoea, regarding the irradiated
small-bowel volume were seen in the range of low radi-
ation doses. Possibilities to reduce the volume of the irradi-
ated small-bowel are prone positioning of the patient with
a belly-board to achieve a small-bowel displacement away
from the radiation field and application of highly con-
formal treatment approaches, such as intensity-modulated
radiation therapy (IMRT). Several studies showed a signifi-
cant reduction of dose to the small-bowel when using a
belly board and therefore a significant decrease of irradi-
ation induced enteritis [27-29]. IMRT has been applied to
several pelvic malignancies, e. g. gynaecologic malignancy
and anal cancer with reduced dose to the small-bowel and
less toxicity compared to 3D conformal radiotherapy
(3DCRT)[30-32].
In comparison, the data for IMRT in rectal cancer are
relatively spare [33,34]. Mok et al. [34] made a pairwise
comparison between IMRT and 3DCRT plans with re-
spect to dose-volume histogram parameters. They found
IMRT achieved a significant reduction of the mean dose
and the absolute volumes of the small-bowel compared
to the 3DCRT plans. Nevertheless it should be consid-
ered, that this fact applies to middle and high dose vol-
umes and usually low dose volumes were equally or
rather increased by IMRT compared to 3DCRT. There-
fore it is all the more important to consider dose con-
straints during inverse treatment planning. According to
our results the small-bowel volume receiving 5 Gy
should be limited to about 300 cc.Conclusion
There is a significant difference between the small-bowel
volumes and the severity of acute diarrhoea during
nRCT for LARC. The highest significance for developing
grade 2–3 diarrhoea was seen at a dose level of 5 Gy with
a small-bowel volume of about 300 cc. This is clinically
useful information and should be considered in future
treatment planning processes where the small-bowel vol-
ume receiving 5 Gy should be limited to about 300 cc.
Moreover we conclude, that “a little to a lot”, which means
a little dose to a large small-bowel volume should be
avoided to reduce the risk for radiation induced diarrhoea
in contrast to the situation in the lung.It is recommended that appropriate small-bowel dose–
volume constraint using the currently available data
should be introduced into routine inverse treatment plan-
ning for rectal radiotherapy.
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